Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

MedImmune Appoints Development Leadership Team

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Former Cambridge Antibody Technology exec to oversee product development.

You may also be interested in...



AstraZeneca Concentrates Biologics At MedImmune, Ups R&D

MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.

AstraZeneca Hears CAT’s Meow With Biotech Acquisition

Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.

Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement Of The Market’

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest News

EMA To Address Problems With CTIS By Key January Deadline

Pharma Firms Must Act On Biodiversity Footprinting To Avoid Business Risks

Pharma Could Face Fewer False Claims Act Suits If Supreme Court Concurs With Government

Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard

See All
UsernamePublicRestriction

Register

PS067855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By